Proposal for a new model of breast cancer metastatic development

Annals of Oncology

Volumn 8, Issue 11, 1997, Pages 1075-1080

  Demicheli, R ^a   Retsky, M W ^b   Swartzendruber, D E ^b   Bonadonna, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Gompertzian kinetics; Stochastic model; Surgery signals; Tumor dormancy; Tumor growth

Indexed keywords

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER SURGERY; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; HUMANS; KINETICS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; STOCHASTIC PROCESSES;

EID: 0030670991     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008263116022     Document Type: Article

References (47)

1. Crowe JP Jr, Gordon NH, Antunez AR, et al. Local-regional breast cancer recurrence following mastectomy. Arch Surg 1991; 126: 429-32.
2. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 1988; 48: 7067-71.
3. Morz R, Francesconi M, Schemper M et al. The value of prognostic parameters for the stratification of advanced breast cancer patients. J Cancer Res Clin Oncol 1982; 102: 289-99.
4. Roseman J. Perrone T. The metastasis-free interval following curative treatment for breast cancer. Int J Radiat Oncol Biol Phys 1984; 10: 63-7.
5. Tomin R, Donegan WL. Screening for recurrent breast cancer - its effectiveness and prognostic value. J Clin Oncol 1987; 5: 62-7.
6. Kamby C, Bruun Rasmussen B, Kristense B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989; 60: 252-7.
7. Koenders PG. Beex LVAM. Kloppenborg PWC et al. Human breast cancer: Survival from first metastasis. Breast Cancer Res Treat 1992; 21: 173-80.
8. Lionetto R, Pronzato P, Bertelli GF et al. Survival of patients with relapsing breast cancer: Analysis of 302 patients. Oncology 1986; 43: 278-82.
9. Vincent MD, Powles TJ, Skeet R et al. An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. Eur J Cancer Clin Oncol 1986; 22: 1059-65.
10. Vogel CL, Azevedo S, Hilsenbeck S, et al. Survival after first recurrence of breast cancer. Cancer 1992; 70: 129-35.
11. Blanco G, Holli K, Heikkinen M, et al. Prognostic factors in recurrent breast cancer: Relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological grading. Br J Cancer 1990; 62: 142-6.
12. Clark GM, Sledge GW, Osborne CK et al. Survival from first recurrence: Relative importance of prognostic factors in 1015 beast cancer patients. J Clin Oncol 1987; 5: 55-61.
13. Goldhirsch A, Gelber RD, Castiglione M. for the Ludwig Breast Cancer Study Group. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: Patterns and prognosis. J Clin Oncol 1988; 6: 89-97.
14. Rubens RD, Bajetta E, Bonneterre J et al. Treatment of relapse of breast cancer after adjuvant systemic therapy - review and guidelines for future research. Eur J Cancer 1994; 30A: 106-11.
15. Hietanen P, Miettinen M, Makinen J: Survival after first recurrence in breast cancer. Eur J Cancer Clin Oncol 1986; 22: 913-9.
16. Demicheli R, Terenziani M, Valagussa P et al. Local recurrences following mastectomy: Support for the concept of tumor dormancy. J Natl Cancer Inst 1994; 86: 45-8.
17. Demicheli R, Abbattista A, Miceli R et al. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy. Breast Cancer Res Treat 1996; 41: 177-85.
18. Demicheli R, Valagussa P. Bonadonna G. The long-lasting effect of adjuvant CMF in node-positive (N+) breast cancer patients is mainly due to significant reduction of early relapses. Anti-cancer Drugs 1995; 6 (Suppl 2): 77.
19. Holmberg L, Ponten J, Adami HO. The biology and natural history of breast cancer from screening perspective. World J Surg 1989; 13: 25-30.
20. Frisell J, von Rosen A, Wiege MN et al. Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992; 24: 11-6.
21. Meltzer A. Dormancy and breast cancer. J Surg Oncol 1990; 43: 181-8.
22. Uhr JW, Tucker T, May RD et al. Cancer dormancy: Studies of the murine BCL1 lymphoma. Cancer Res 1991; 51: 5045s-53s.
23. Vijsman JH, Cornelisse CJ, Keijzer R et al. A prolactin dependent, metastasising rat mammary carcinoma as a model for endocrinerelated tumor dormancy. Br J Cancer 1991, 64: 463-8.
24. Gartner MF, Fearns C, Wilson EL, et al.: Unusual growth characteristics of human melanoma xenografts in the nude mouse: A model for desmoplasia, dormancy and progression. Br J Cancer 1992; 65: 487-90.
25. Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 1981 ; 67: 51-6.
26. Holmgren L. O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-53.
27. Pantel K, Schlimok G, Braun S: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993; 85: 1419-24.
28. Killion JJ, Fidler IJ. The biology of tumor metastasis. Semin Oncol 1989; 16: 106-15,1989.
29. Sobel ME. Metastasis suppressor genes. J Natl Cancer Inst 1990; 82: 267-76.
30. Nicolson GL. Molecular mechanisms of cancer metastasis: Tumor and host properties and the role of oncogenes and suppressor genes. Curr Opin Oncol 1991; 3: 75-92.
31. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
32. Lin WC, Pretlow TP, Pretlow II TG et al. Development of micrometastases: earliest events detected with bacterial lacZ genetagged tumor cells. J Natl Cancer Inst 1990; 82: 1497-1503.
33. O'Reilly MS, Holmgren L, Shing Yet al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
34. Braunschweiger PG, Schiffer LM, Betancourt S. Tumor cell proliferation and sequential chemotherapy after partial tumor resection in C3H/HeJ mammary tumors. Breast Cancer Res Treat 1982; 2: 323-9.
35. Gunduz N, Fisher B. Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39: 3861-5.
36. Fisher B, Gunduz N, Coile J et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
37. Speer J, Petrosky V, Retsky M et al. A stochastic numerical model of breast cancer that simulates clinical data. Cancer Res 1984; 44: 4124-30.
38. Folkman J, Watson K, Ingber D et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61.
39. Kandel J, Bossy-Wetzel E, Radvanyi F et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991; 66: 1095-1104.
40. Laird AK. Dynamics of tumor growth. Br J Cancer 1964; 18: 490-502.
41. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1991; 339: 1-15, 71-85.
42. Nissen-Meyer R, Kjellgren K, Malmio K et al. Surgical adjuvant chemotherapy. Cancer 1978; 41: 2088-98.
43. The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989: 320: 491-6.
44. Valagussa P, Brambilla C. Zambetti M et al. Salvage treatments in relapsing resectable breast cancer. Recent Results Cancer Res 1989; 115: 69-76.
45. Greenberg PAC, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 1996; 2197-2205.
46. The International Breast Cancer Study Group: Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996; 14: 1885-94.
47. Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992; 127: 1303-8.